Riggs, Kari L.
Wiseman, Scott
Article History
Received: 3 February 2021
Accepted: 3 May 2021
First Online: 28 May 2021
Declarations
:
: The study was based on the guidelines for evaluating the target animal safety of new pharmaceuticals [VICH Guideline 43, and to recognized quality assurance standards (United States Food and Drug Administration (FDA) Good Laboratory Practice (GLP) Regulations, 21 Code of Federal Regulations (CFR) Part 58 and the Organisation for Economic Co-operation and Development (OECD) Series on Principles of Good Laboratory Practice)]. The study was reviewed and approved by the CRL-Ashland’s Institutional Animal Care and Use Committee. This manuscript was prepared in compliance with the ARRIVE Guidelines Checklist for animal in vivo experiments.
: Not applicable.
: These studies were funded by Elanco Animal Health. All authors are employees of Elanco Animal Health. The handling editors have been involved in consulting services (Filipe Dantas-Torres), research projects (Pablo JesúsBorrás, Filipe Dantas-Torres, Adnan Hodžic) and meetings (Filipe Dantas-Torres) sponsored by different veterinary pharmaceutical companies in the past 10 years, including Elanco. They declare that each manuscript in this collectionwas handled impartially and peer reviewed rigorously by at least two independent external reviewers.